Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Voyager Therapeutics Inc VYGR.OQ reported a quarterly adjusted loss of 59 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $1.25. The mean expectation of twelve analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -52 cents to -13 cents per share.

• Revenue fell 93% to $6.28 million from a year ago; analysts expected $16.58 million.

• Voyager Therapeutics Inc's reported EPS for the quarter was a loss of 59 cents​.

• The company reported a quarterly loss of $34.49 million.

• Voyager Therapeutics Inc shares had fallen by 26.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Voyager Therapeutics Inc is $16.00

This summary was machine generated from LSEG data March 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)